Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
1.649 / 16.983
#13185

Re: Farmas USA

Alguno estais siguiendo a Knight Capital Group Inc. ?

http://www.google.com/finance?q=NYSE:KCG

Vaya remontada que se esta pegando, ayer un error le produjo 400 Millones en perdidas y bajo un -67% , hoy en el premarket andaba con un -20% y ahora sube un 60%, vaya locura, hace unos minutos subia "solo" un 40% .

Saludos

#13186

Re: Farmas USA

voy largo en thld.
el resto son opiniones.

#13187

Re: Farmas USA

Os habéis fijado lo bien que va ECYT hoy?

#13189

Re: Farmas USA

En mi broker vuelven a dejar abrir cortos en ARNA, apañaos vamos.

#13190

Re: Farmas USA

yo abri cortos en el ibex el otro dia y estaban prohibidos.
asi es clicktrade tran pronto te deja como no

#13191

Re: Farmas USA

Hola a todos.
Aquí va mi aportación tardía. Casi mejor esperar a ver que hace el lunes pero esa línea parece de acero...
Dió resultados financieros ayer.

Pain Therapeutics

Pain Therapeutics

PTIE

PTIE

#13192

Re: Farmas USA

Suena bien...

AUSTIN, Texas, Aug. 2, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE) today reported financial results for the quarter and six months ended June 30, 2012. Net loss for Q2 2012 was $0.1 million, or $0.00 per share, as compared to the net loss in Q2 2011 of $1.2 million, or $0.03 per share. Net loss for the first half of 2012 was $0.1 million, or $0.00 per share, as compared to net loss for the first half of 2011 of $1.4 million, or $0.03 per share.

Cash and investments were $93.9 million at June 30, 2012. Actual net cash usage for the first half of 2012 was $4.2 million, versus guidance of $5.0 million. The Company has no debt.

Management continues to believe net cash usage for 2012 will be under $10.0 million.

"Financial results reflect our goal to maintain tight financial discipline while waiting for the regulatory resubmission of REMOXY by our partner, Pfizer," said Remi Barbier, Chairman, President & CEO of Pain Therapeutics. "We remain excited by the prospect of having a potential first-in-class oxycodone drug in a $3+ billion market."

Brokers destacados